EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lumican Is Both a Novel Risk Factor and Potential Plasma Biomarker for Vascular Aging, Capable of Promoting Vascular Smooth Cells Senescence Through Interacting With Integrin α2β1

Mandi Luo, Dan Yan, Yi Huang, Tianyi Ji, Pengcheng Luo, Zhen Yang, Shangbang Gao iD, Le Zhang iD, Yiwu Zhou, Qing Shi, Yongping Bai iD, Tao Li und 2 weitere

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences · 2024

DOI: 10.1093/gerona/glae214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2024. Verfasst von Mandi Luo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Lumican, Cellular Senescence, Integrin alpha2beta1, Aging. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key R&D Program of China, Major Technology Innovation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular aging, a common pathogenesis of senile chronic diseases, significantly increases morbidity and mortality in older adults; its intricate cellular and molecular mechanisms necessitate further investigation. Lumican (LUM) and integrin α2β1 are profibrotic extracellular matrix proteins and vital cell regulatory receptors, respectively. However, their roles in vascular aging remain unclear. This study sought to elucidate the connection between LUM and vascular aging as well as the biological mechanism of LUM/integrin α2β1 in this process. Using an enzyme-linked immunosorbent assay, we discovered that plasma LUM was elevated in vascular aging individuals and was positively correlated with brachial-ankle pulse wave velocity. Additionally, immunohistochemical and Western blot analyses confirmed LUM upregulation in arteries of older adults and aged mice, as well as in senescent vascular smooth cells (VSMCs). Wild-type and LUM semiknockout (Lum−/+) mice, along with primary VSMCs extracted from these mice, were exposed to angiotensin II to induce a stress-induced senescence model. LUM semiknockout mitigated angiotensin II-induced arteriosclerosis, hypertension, vascular aging, and remodeling in mice. Both in vitro and in vivo studies revealed that LUM deficiency suppressed p53, p21, collagen 1, and collagen 3 upregulation and synthetic phenotype formation in VSMCs stimulated by angiotensin II. Treating VSMCs with an integrin α2β1 antagonist reversed the aforementioned changes triggered by LUM proteins. Briefly, LUM functions as a potential marker and risk factor for vascular aging and promotes pathological changes by affecting integrin α2β1 in VSMCs. This study introduces a novel molecular target for the early diagnosis and treatment of vascular aging and age-related vascular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LumicanCellular SenescenceIntegrin alpha2beta1AgingBiomarkersMuscle, Smooth, VascularAnimalsMiceHumansMaleRisk FactorsAgedFemaleMice, Inbred C57BLMiddle AgedAngiotensin IIPulse Wave Analysis

Stichwörter der Autor:innen

LUMPulse wave velocitySynthetic phenotypeVSMCsVascular aging

Substanzen

LumicanIntegrin alpha2beta1BiomarkersAngiotensin IILUM protein, human

Autor:innen und Institutionen

  • Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Sciences and Technology, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Forensic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Geriatrics Medicine, Center of Coronary Circulation, Xiangya Hospital, Central South University, Changsha, China.
  • BGI Genomics, Shenzhen, China.

ORCID-Profile: Shangbang Gao, Le Zhang, Yongping Bai

Förderung

  • National Key R&D Program of China
  • Major Technology Innovation of Hubei Province

Zitieren

APA

Luo, M., Yan, D., Huang, Y., Ji, T., Luo, P., Yang, Z., Gao, S., Zhang, L., Zhou, Y., Shi, Q., Bai, Y., Li, T., Ruan, L., & Zhang, C. (2024). Lumican Is Both a Novel Risk Factor and Potential Plasma Biomarker for Vascular Aging, Capable of Promoting Vascular Smooth Cells Senescence Through Interacting With Integrin α2β1. The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences. https://doi.org/10.1093/gerona/glae214

Vancouver

Luo M, Yan D, Huang Y, Ji T, Luo P, Yang Z, et al. Lumican Is Both a Novel Risk Factor and Potential Plasma Biomarker for Vascular Aging, Capable of Promoting Vascular Smooth Cells Senescence Through Interacting With Integrin α2β1. The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences. 2024. doi:10.1093/gerona/glae214

BibTeX
@article{Luo2024,
  author = {Luo, Mandi and Yan, Dan and Huang, Yi and Ji, Tianyi and Luo, Pengcheng and Yang, Zhen and Gao, Shangbang and Zhang, Le and Zhou, Yiwu and Shi, Qing and Bai, Yongping and Li, Tao and Ruan, Lei and Zhang, Cuntai},
  title = {Lumican Is Both a Novel Risk Factor and Potential Plasma Biomarker for Vascular Aging, Capable of Promoting Vascular Smooth Cells Senescence Through Interacting With Integrin α2β1},
  journal = {The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences},
  year = {2024},
  doi = {10.1093/gerona/glae214}
}
Kostenlos starten →